Reviewing Shattuck Labs (NASDAQ:STTK) and Williston (OTCMKTS:WHCA)

Williston (OTCMKTS:WHCA) and Shattuck Labs (NASDAQ:STTK) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Profitability

This table compares Williston and Shattuck Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Williston	N/A	N/A	N/A
Shattuck Labs	N/A	-81.80%	-71.46%

Valuation and Earnings

This table compares Williston and Shattuck Labs”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Williston	N/A	N/A	N/A	N/A	N/A
Shattuck Labs	$5.72 million	14.99	-$75.41 million	($1.21)	-1.48

Williston has higher earnings, but lower revenue than Shattuck Labs.

Analyst Ratings

This is a summary of current ratings and target prices for Williston and Shattuck Labs, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Williston	0	0	0	0	0.00
Shattuck Labs	0	3	2	2	2.86

Shattuck Labs has a consensus price target of $4.00, indicating a potential upside of 123.46%. Given Shattuck Labs’ stronger consensus rating and higher probable upside, analysts clearly believe Shattuck Labs is more favorable than Williston.

Institutional and Insider Ownership

58.7% of Shattuck Labs shares are held by institutional investors. 12.0% of Shattuck Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Shattuck Labs beats Williston on 7 of the 9 factors compared between the two stocks.

About Williston

Williston Holding Company, Inc. owns and operates restaurants. The company was incorporated in 2012 and is based in Eden Prairie, Minnesota.

About Shattuck Labs

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.